Riya, a 34-year-old marketing professional in Mumbai, had tried everything—intermittent fasting, gym memberships, and multiple diet trends. Despite temporary success, nothing worked sustainably. When she heard about a weekly weight-loss injection, it seemed like the breakthrough she had been waiting for. Within a few months, she lost over 12 kilograms with minimal effort.
However, the transformation came with unintended consequences. Riya began experiencing persistent fatigue, noticeable hair thinning, and a general sense of weakness. What initially appeared to be a miracle solution began to raise concerns about what was happening beneath the surface. Her experience reflects a broader trend now emerging across India.
New Chapter in Metabolic Health
GLP-1 receptor agonists represent one of the most significant advances in the management of obesity and type 2 diabetes. These medications work by enhancing insulin secretion, slowing gastric emptying, and reducing appetite. Large clinical trials have consistently demonstrated weight loss of 10–20%, along with meaningful improvements in glycaemic control.
With recent patent expiries, these therapies are becoming significantly more affordable in India. This has the potential to improve access for millions of patients who previously could not afford such treatments. However, rapid expansion in access, without adequate medical supervision, introduces new and complex risks.
Double-Edged Sword of Rapid Adoption
The increasing availability of these drugs has led to a shift from medically supervised use to consumer-driven demand. Many individuals are initiating therapy without appropriate evaluation or guidance. There is also a growing trend towards using these medications for cosmetic weight loss rather than medical necessity.
Easy access through pharmacies, online platforms, and wellness clinics has further amplified the problem. In such settings, the absence of structured monitoring increases the likelihood of inappropriate dosing, unmanaged side effects, and poor long-term outcomes.
What the Science Says About Risks
Clinical evidence highlights that not all weight loss achieved with these medications is beneficial. A significant proportion, up to 25–40 per cent, can be attributed to the loss of lean muscle mass. This has important implications, including a reduced metabolic rate, increased fatigue, and a higher risk of weight regain.
Additionally, reduced appetite often leads to inadequate nutritional intake. Deficiencies in protein, vitamin B12, iron, and vitamin D are increasingly observed. Over time, this can manifest as weakness, hair loss, reduced immunity, and impaired overall health.
Gastrointestinal side effects such as nausea, vomiting, and constipation are common. While generally manageable under medical supervision, they can lead to dehydration and electrolyte imbalances if ignored.
Importantly, these medications do not cure obesity. Discontinuation without sustained lifestyle changes frequently results in weight regain, highlighting the need for long-term management strategies.
Why India May Be More Vulnerable
India presents a unique metabolic profile, characterized by lower baseline muscle mass, higher body fat percentage at lower BMI levels, and diets that are often deficient in high-quality protein. These factors increase susceptibility to adverse outcomes such as sarcopenia and nutritional deficiencies during rapid weight loss.
The influx of multiple generic versions has further complicated the landscape. Variability in dosing practices, device formats, and patient education contributes to confusion and increases the risk of misuse.
Crucial Role of Regulation
As access expands, regulatory oversight becomes essential to ensure safe and appropriate use. Enforcing prescription-only dispensing, restricting unregulated online sales, and curbing misleading advertising are necessary steps.
Strengthening supply chain monitoring is equally important to prevent substandard or counterfeit products. Regulation should aim to balance accessibility with patient safety, ensuring that these therapies are used responsibly.
Physician-Led Care: Basis of Safe Use
GLP-1 therapies require structured medical management. Appropriate patient selection based on clinical criteria, careful dose titration, and regular monitoring of metabolic parameters are critical components of effective treatment.
A multidisciplinary approach involving physicians, nutritionists, and fitness professionals can significantly improve outcomes. Integrating dietary planning, particularly adequate protein intake, and resistance training helps preserve muscle mass and enhances long-term success.
Pharmaceutical Industry’s Responsibility
Pharmaceutical companies play a crucial role in shaping how these therapies are perceived and used. Ethical promotion that emphasises long-term health benefits rather than quick weight loss is essential.
Investing in physician education ensures appropriate prescribing practices. Patient support programmes that include dietary guidance, exercise recommendations, and adherence monitoring can further improve outcomes.
Maintaining high standards of manufacturing quality and ensuring proper cold-chain logistics are fundamental responsibilities, particularly in a rapidly expanding market.
Shift in Mindset
The most important shift is in perception. These medications are not cosmetic solutions or shortcuts. They are chronic-disease therapies that require structured, long-term management.
When integrated into a comprehensive care plan, they can significantly improve metabolic health and quality of life. When used in isolation or without guidance, they risk creating new health challenges.
Conclusion
Riya eventually sought medical advice and adopted a more structured approach, incorporating nutritional support and strength training. Her energy levels improved, and her progress became sustainable. Her journey underscores a critical lesson: access alone is not enough. The true benefit of these therapies lies in how they are used.
India stands at a pivotal moment. With the right balance of regulation, physician oversight, and industry responsibility, this therapeutic revolution can deliver meaningful and lasting health outcomes.
(Dr Anish Desai is a healthcare entrepreneur. He is leading IntelliMed Healthcare Solutions)
